Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 4/20 | 0.53 |
| ▸ | BRAF | P15056 | 4/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 2/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | GRK2 | P25098 | 1/20 | 0.41 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.41 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4139488 | 0.81 | NR4A2 (0.49) | NR4A2MAP4K4 | |
| SCHEMBL4153922 | 0.78 | NR4A2 (0.53) | ALDH1A1NR4A2MAP4K4MET | |
| SCHEMBL24252651 | 0.75 | MAP4K4 (0.44) | RAF1BRAFALDH1A1NR4A2KIT | |
| SCHEMBL9464193 | 0.74 | CYP17A1 (0.61) | PDGFRBPDGFRANPC1ALDH1A1RAB9A | |
| Amiquinsin SCHEMBL242841 | 0.74 | EHMT2 (0.63) | PDGFRBPDGFRAEHMT2EHMT1 | |
| SCHEMBL26771324 | 0.74 | MAP4K4 (0.44) | RAF1BRAFALDH1A1NR4A2KIT | |
| SCHEMBL2855768 | 0.73 | PDGFRB (0.60) | PDGFRBPDGFRANPC1ALDH1A1RAB9A | |
| SCHEMBL183019 | 0.73 | PIK3CD (0.64) | RAF1BRAFPDGFRBPDGFRAKIT | |
| SCHEMBL182735 | 0.73 | PIK3CD (0.64) | RAF1BRAFPDGFRBPDGFRAKIT | |
| SCHEMBL25946726 | 0.72 | ALDH1A1 (0.57) | PDGFRBPDGFRANPC1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069338-A1 | Method for predicting skin sensitizing activity of compounds | DICKSON JR JOHN K | 2009-03-12 | — | — | US | disclosed |
| US-7452887-B2 | Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | AMPHORA DISCOVERY CORPORATION (US) | 2008-11-18 | — | — | US | disclosed |
| US-20060009460-A1 | Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | AGRIUS GROUP, LLC. | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069338-A1 | Method for predicting skin sensitizing activity of compounds | ATP5ME, ABCG2, ATP5MG | RAF1 2420/4885BRAF 2872/4885PDGFRB 4646/4885 |
| US-20060009460-A1 | Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | ATP5ME, ATP5MG, ATP5MK | RAF1 1972/4885BRAF 2923/4885PDGFRB 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.